Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1384-1390

  Propper, David ^a   Davidenko, I ^b   Bridgewater, J ^c   Kupcinskas, L ^d   Fittipaldo, A ^e   Hillenbach, C ^f   Klughammer, B ^f   Ducreux, M ^g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b State Institution of Public Health Regional Clinical Oncology Dispensary   (Russian Federation)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biomarkers; Erlotinib; Pancreatic cancer; Personalized therapy; Predictive markers

Indexed keywords

AMPHIREGULIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; K RAS PROTEIN; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; COPY NUMBER VARIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EGFR GENE; EXPLORATORY RESEARCH; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TUMOR BIOPSY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PLACEBOS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84903729284     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu176     Document Type: Article

References (18)

1. Samuel N, Hudson TJ. The molecular and cellular heterogenecity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 9: 77-87.
2. Burris H, III, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008; 13: 289-298.
3. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
4. Cunha Santos G, Dhani N, Tu D et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010; 116: 5599-5607.
5. Epelbaum R, Schnaider J, Gluzman A et al. Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium, Orlando, FL, 19-21 January 2007. Abstract 202.
6. Common Terminology Criteria for Adverse Events v3.0 (CTCAE): The NCI Common Terminology Criteria for Adverse Events. Bethesda, MD: Cancer Therapy Evaluation Program, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ctcaev3.pdf (11 June 2014, date last accessed).
7. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
8. Van Cutsem E, Köhne C-H, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
9. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
10. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
11. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
12. Yokoyama M, Ebert M, Funatomi H et al. Amphiregulin is a potent mitogen in human pancreatic-cancer cells-correlation with patient survival. Int J Oncol 1995; 6: 625-631.
13. Wilson KJ, Mill C, Lambert S et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 2012; 30: 107-116.
14. Willmarth NE, Baillo A, Dziubinski ML et al. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 2009; 21: 212-219.
15. Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-3921.
16. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-447.
17. Lee J, Jang KT, Ki CS et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561-1569.
18. Jamieson NB, Carter CR, McKay CJ et al. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 2011; 17: 3316-3331.